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TO THE EDITOR
Identification of markers that predict
the response to a targeted therapy is a
key goal for the treatment of melanoma.
A major advance was the observation
that certain subtypes, such as mucous
membrane melanoma and acral lenti-
ginous melanoma, are frequently asso-
ciated with activating mutations in the
KIT oncogene (Curtin et al., 2006).
Imatinib mesylate, a small-molecule in-
hibitor of protein tyrosine kinases, has
been used with considerable success in
the treatment of gastrointestinal stromal
tumors, which are induced by abnormal
activation and overexpression of the KIT
receptor in 90% of cases (Sleifjer et al.,
2008). Recent reports have described the
usefulness of this molecule in the treat-
ment of rectal (Hodi et al., 2008) and
acral lentiginous melanoma (Kim et al.,
2008). Here, we report a patient with a
rapid response to imatinib in a lung
metastasis from an acral lentiginous
melanoma. Surprisingly, this was paral-
leled by progressive disease of locore-
gional lymph node metastasis.
A 64-year-old woman was admitted
because of progressive severe dyspnea
at rest. A pulmonary mass obstructing
the left main bronchus was revealed
by computed tomographic scanning
(Figure 1a). Grayish pigmentation on
her left big toe revealed an acral
lentiginous melanoma. Computed tomo-
graphic imaging of the abdomen and
pelvis excluded visceral metastases but
revealed lymph node metastases in the
left ilioinguinal region (Figure 1b). Biopsy
specimens were excised from the skin
and lymph nodes and by incision via
endoluminal access from the pulmonary
mass. Probes were processed for routine
histology and immunohistochemistry
and preserved for molecular biology.
Our studies were conducted after obtain-
ing written informed consent and institu-
tional review board approval and were in
compliance with the Declaration of
Helsinki Principles.
Histopathology of the skin pigmen-
tation confirmed the diagnosis and
revealed parts of an acral lentiginous
melanoma (not shown). Histopathology
of both the lung (Figure 1c) and lymph
node (Figure 1d) biopsies showed
highly proliferative atypical epithelioid
cells. Expression analysis by immuno-
histochemistry using a specific mono-
clonal mouse antibody against KIT
(CD117) revealed that both metastases
showed the presence of KIT; however,
the lung specimen (Figure 1e) expressed
the protein more brightly and uniformly
than did the lymph node metastasis
(Figure 1f). Furthermore, S100, Melan-A,
and HMB-45 were positively stained in
both probes (Figures 1g and h). We
initiated monotherapy with imatinib
mesylate (Glivec, Novartis Pharma
Nu¨rnberg, Germany) 400 mg once dai-
ly. After 6 weeks, radiological reassess-
ment of the chest showed regression of
the pulmonary mass; the largest dia-
meter had decreased from 3.2 to
2.0 cm. Moreover, the atelectasis of
the left upper lobe had reversed com-
pletely (Figure 1i). The performance
status was remarkably improved.
However, the lymph node metastasis
in the left groin showed marked pro-
gression; the largest diameter had
increased from 3.0 to 5.8 cm in the
inguinal node (Figure 1j) and from 2 to
3 cm in the iliacal node (not shown).
In an effort to understand this differ-
ential biological behavior of the two
tumor manifestations, we investigated
the KIT mutation status of the primary
tumor, the lymph node, and the lung
metastases. To this end, genomic DNA
was extracted and exons 11, 13, 17,
and 18 of the KIT gene, which harbor
the vast majority of mutations identified
in human tumors, were analyzed by
PCR amplification followed by direct
sequencing. Interestingly, in both the
primary tumor and the lymph node
metastasis, we detected only wild-type
sequences, whereas in the lung metas-
tasis, a homo- or hemizygous nucleotideAbbreviation: CT, computed tomography
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exchange, t1676c, was revealed in exon
11, which codes for a V559A mutation.
This mutation has previously been de-
scribed in gastrointestinal stromal tumors
as well as in melanoma, and it was
shown to render the KIT kinase constitu-
tively active and transforming (Nishida
et al., 1998; Curtin et al., 2006). Curtin
et al. (2006) reported KIT aberrations in
21% of mucosal and 11% of acral
lentiginous melanomas. Interestingly, in
their study the V559A mutation prevail-
ing in gastrointestinal stromal tumors
was observed only in mucosal melano-
mas. In fact, to the best of our knowl-
edge, this is the first report of the V559A
mutation in acral lentiginous melanoma.
We previously reported that imatinib,
used in a nonselected melanoma patient
population, lacked clinical efficacy
(Becker et al., 2007). We also recently
demonstrated that the sole overexpression
of KIT measured by immunohistochem-
istry is not suitable for patient selection
(Hofmann et al., 2009). In contrast, when
imatinib is given to melanoma patients on
the basis of the presence of activating KIT
mutations, the clinical response can be
remarkably good.
In this case report, we have de-
scribed a patient with two metastases of
an acral lentiginous melanoma with
unequal KIT mutation status: Although
the tested distant lung metastasis
harbored the V559A mutation, the
primary tumor and locoregional metas-
tasis showed the normal homozygous
wild-type gene. It is noteworthy that
only the metastasis with the mutation
responded to imatinib therapy. Thus,
the mutational status of corresponding
tumor lesions is highly predictive for
therapy outcome. It therefore seems
crucial to identify the target on the
genetic level when imatinib mesylate is
considered in metastasized melanoma.
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Figure 1. Response to therapy and molecular characteristics of the metastases. (a) Chest computed
tomography (CT) image before therapy: a pulmonary mass beneath the aorta ascendens (arrow)
obstructing the left primary bronchus and atelectasis. (b) CT image of the pelvis before therapy: inguinal
lymph node metastasis is on the left (arrow). (c) Histopathology, lung metastasis. Bar¼100 mm.
(d) Histopathology, lymph node metastasis. Bar¼100 mm. (e) Immunohistochemical staining for KIT
(CD117), lung metastasis. Bar¼ 100mm. (f) Immunohistochemical staining for KIT (CD117), lymph node
metastasis. Bar¼ 100 mm. (g) Immunohistochemical staining for melanoma markers (Melan-A was used),
lung metastasis. Bar¼ 100mm. (h) Immunohistochemical staining for Melan-A, lymph node metastasis.
Bar¼100 mm. (i) Chest CT image after 6 weeks of therapy showing regression of lung metastasis. (j) Pelvis
CT image after 6 weeks of therapy showing progression of lymph node metastasis.
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Cutaneous-Type Adult T-Cell Leukemia/Lymphoma Does
Not Primarily Show Deletion of NAV3 Gene
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TO THE EDITOR
Adult T-cell leukemia/lymphoma
(ATLL) is a peripheral T-cell neoplasm
caused by human T-cell leukemia virus
type 1 (Ohshima et al., 2008). There are
four clinical subtypes of ATLL: acute,
lymphoma, chronic, and smoldering
(Shimoyama, 1991). Although acute
and lymphoma types are associated
with a highly aggressive clinical course,
chronic and smoldering types usually
have an indolent course. More than half
of ATLL patients present with cutaneous
lesions (Ohshima et al., 2008). In some
cases skin is the only site of lymphoma
involvement and there is no involve-
ment of other organs including periph-
eral blood and lymph nodes. These
cases are considered to be the primary
cutaneous form of ATLL and have been
designated as cutaneous type (Johno
et al., 1992), although they are in-
cluded among the smoldering type
according to the current classification
(Shimoyama, 1991). Prognosis of cuta-
neous-type ATLL, especially those with
cutaneous tumors, is worse than that of
smoldering type without cutaneous in-
volvement (Johno et al., 1992; Setoya-
ma et al., 1999; Yamaguchi et al.,
2005; Bittencourt et al., 2007, 2009).
However, cutaneous-type patients who
present only with patches and/or
plaques, clinically and histologically
indistinguishable from lesions of myco-
sis fungoides (MF), may develop cuta-
neous tumors or extracutaneous disease
only after a protracted period (Johno
et al., 1992; Setoyama et al., 1999;
Bittencourt et al., 2007, 2009). Differ-
ential diagnosis of these cases from MF
is often difficult and can be made only
by demonstration of the clonal integra-
tion of human T-cell leukemia virus type
1 proviral DNA in the cutaneous lesions.
Important roles of the human T-cell
leukemia virus type 1 Tax protein
(Peloponese et al., 2007) and basic
zipper factor mRNA (Satou and Matsuo-
ka, 2007) in the oncogenesis of ATLL
have been established. The long latency
period before onset of ATLL indicates that
in addition to viral components, cytoge-
netic changes acquired over time in the
host genome of human T-cell leukemia
virus type 1-infected T cells would be
required for the development of full-
blown ATLL (Okamoto et al., 1989).
Although genetic and epigenetic aberra-
tions that may be associated with the
oncogenesis of particular types of ATLL
or disease progression have been re-
ported (Kamada et al., 1992; Nosaka
et al., 2000; Itoyama et al., 2001;
Tsukasaki et al., 2001; Yasunaga et al.,
2004; Sasaki et al., 2005; Yamada and
Kamihira, 2005; Oshiro et al., 2006), no
cytogenetic hallmark of ATLL has been
identified. Furthermore, these abnormal-
ities are found mainly in the aggressive
(acute and lymphoma) types (Kamada
et al., 1992; Itoyama et al., 2001;
Tsukasaki et al., 2001; Sasaki et al.,
2005; Yamada and Kamihira, 2005;
Oshiro et al., 2006), and no specific
cytogenetic aberration has been identi-
fied in the indolent types including the
cutaneous type.
Deletion or disrupting translocation
of NAV3 (neuron navigator 3) gene is a
recently described recurrent cytoge-
netic abnormality in MF and related
Se´zary syndrome (Karenko et al., 2005).
Although some of the subsequent stu-
dies by other groups failed to confirm
this finding (Carbone et al., 2008; Marty
et al., 2008), the discrepancy might be
explained by the different case series
analyzed or by the different detection
methods used in these studies (Karenko
et al., 2005; Carbone et al., 2008;
Marty et al., 2008; Vermeer et al.,
2008). Allelic NAV3 deletion has also
been shown to have a role in the
oncogenesis of subcutaneous pannicu-
litis-like T-cell lymphoma (Hahtola
et al., 2008a) and other cancers (Hah-
tola et al., 2008b; Bleeker et al., 2009;
Soon et al., 2009). Importantly, NAV3
gene deletion may be a relatively early
event in the development of MF,
because it was found in 50% of the
early MF cases (Karenko et al., 2005).
The close clinical and histological
resemblance between cutaneous-type
ATLL with MF-like manifestations and
early MF led us to hypothesize that
NAV3 deletion has a role also in the
oncogenesis of cutaneous-type ATLL.
To determine whether aberrations of
NAV3 gene are present in ATLL, we
analyzed the status of NAV3 gene in
cutaneous lesions of ATLL, in particular
those of cutaneous type, by multicolor
fluorescence in situ hybridization on
interphase nuclei isolated from paraffin-
embedded skin biopsy samples (Karen-
ko et al., 2005; Hahtola et al., 2008b).
Locus-specific fluorescence in situ hy-
bridization using bacterial artificial
chromosome probes covering NAV3
gene and a chromosome 12 centro-
mere-specific probe was performed asAbbreviations: ATLL, adult T-cell leukemia/lymphoma; MF, mycosis fungoides
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Absence of NAV3 Deletion in Cutaneous ATLL
